Top Markets
#1 0G 0G +43.07%
#2 Merlin's Seal BTC Merlin's Seal BTC +42.87%
#3 Useless Coin Useless Coin +29.81%
#4 SAFEcoin SAFEcoin +28.61%
#5 StonkBroker StonkBroker +28.19%
#6 Pons Pons +24.78%
#7 Zora Zora +21.88%
#8 Dogs Dogs +20.90%
#9 ICON ICON +20.51%
#10 Dash Dash +18.26%
Coin of the day
0G 0G
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Wuhan Hiteck Biological Pharma Co.,Ltd Wuhan Hiteck Biological Pharma Co.,Ltd

Wuhan Hiteck Biological Pharma Co.,Ltd

300683
Classifica tra le azioni #13466
Wuhan Hiteck Biological Pharma Co.,Ltd is a biopharmaceutical enterprise... Wuhan Hiteck Biological Pharma Co.,Ltd is a biopharmaceutical enterprise operating in China, primarily engaged in the research, development, manufacturing, and commercialization of bio-engineered products and lyophilized injectable medications. The company's extensive product portfolio encompasses a variety of pharmaceutical solutions, such as Jinlujie, a mouse nerve growth factor for injection; omeprazole sodium for injection; cyclic adenosine phosphate; Xinye acyclovir tablets; Bingbing Horse & Dragon, an indomethacin furazolidone suppository; Xunkeyuan tinidazole suppository; and Shufu nimodipine sustained-release tablets. Beyond therapeutics, Wuhan Hiteck also provides a comprehensive array of diagnostic kits. These include tests for measles virus and rubella virus nucleic acid, mycoplasma isolation and identification, bacterial vaginosis rapid detection, measles virus IgG antibodies, and the coronavirus N-protein. Furthermore, the firm supplies active pharmaceutical ingredients (APIs) and their chemical intermediates, notably Lopinavir and Ritonavir. Its core therapeutic areas of focus are the nervous system and oncology. Established in 1992, Wuhan Hiteck Biological Pharma Co.,Ltd is headquartered in Wuhan, China.
Prezzo delle azioni
$3.71
Capitalizzazione di mercato
$486.16M
Variazione (1 giorno)
-0.97%
Variazione (1 anno)
-45.64%
Paese
CN
Scambia Wuhan Hiteck Biological Pharma Co.,Ltd (300683)

Categoria

Healthcare
Ricavi di Wuhan Hiteck Biological Pharma Co.,Ltd (300683)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Wuhan Hiteck Biological Pharma Co.,Ltd, i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Wuhan Hiteck Biological Pharma Co.,Ltd da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $6.61B -
IN
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH